Application of Optogenetics in the Regulation of Neural Circuits in Parkinson’s Disease
DOI:
https://doi.org/10.61173/sh8b4a21Keywords:
optogenetics, neural circuits, Parkinson’s diseaseAbstract
This paper reviews the application of optogenetics in the study of Parkinson’s disease and discuss how optogenetics stimulates specific neural circuits to regulate the symptoms and behaviors of Parkinson’s disease. Optogenetics technology has a higher spatial resolution than traditional electrical stimulation, and optogenetics can accurately control specific neuron populations, providing a new perspective for studying PD and exploring potential treatments. The researchers found that selective optogenetic stimulation of the dorsal striatum was sufficient to induce levodopalike dyskinesia in 6-hydroxydopamine (6-OHDA)-induced PD rat models. In addition, the researchers found that transplanted dopamine neurons can correct some of the motor deficits through their neural activity, including dopamine release and synaptic transmission. Although the utility of optogenetic techniques in human patients is unclear, the precise control of neural circuits in animal models provides an important way to understand the mechanisms and side effects of DBS therapy. The study also suggests that optogenetic stimulation of glutamatergic neurons in the mesocerebellar nucleus may improve motor function in PD mouse models, providing a new potential target for PD treatment. Finally, the article discusses how optogenetic technology can be transformed from a research tool into a treatment for PD, and how to repair damaged neural circuits through optogenetic technology to provide a more durable and effective treatment.
References
[1] Hernández L. F., Castela I., Ruiz-DeDiego I., et al. Striatal activation by optogenetics induces dyskinesias in the 6-hydroxydopamine rat model of Parkinson disease. Movement Disorders, 2017, 32(4): 530-537.
[2] Chi X., Niu C.-S. Advances in neural circuit mechanism in Parkinson‘s disease. Chinese Journal of Contemporary Neurology & Neurosurgery, 2020, 20(12).
[3] Chen Y., Hong M., Zhang S. C. Illuminating Parkinson‘s therapy with optogenetics. Nature Biotechnology, 2015, 33(2): 149-150.
[4] Parker K. L., Kim Y., Alberico S. L., et al. Optogenetic approaches to evaluate striatal function in animal models of Parkinson disease. Dialogues in Clinical Neuroscience, 2016, 18(1): 99-107.
[5] Yoon H. H., Min J., Jeon S. R. Optogenetics to restore neural circuit function in Parkinson’s disease. Journal of Neurorestoratology, 2018, 6(1): 88-92.
[6] Gittis A. H., Yttri E. A. Translating insights from optogenetics into therapies for Parkinson‘s disease. Current Dean&Francis Opinion in Biomedical Engineering, 2018, 8: 14-19.
[7] Fougère M., van der Zouwen C. I., Boutin J., et al. Optogenetic stimulation of glutamatergic neurons in the cuneiform nucleus controls locomotion in a mouse model of Parkinson’s disease. Proceedings of the National Academy of Sciences, 2021, 118(43): e2110934118.
[8] Application of optogenetic techniques in the study of neural circuits in brain diseases. Chinese Clinical Neuroscience, 2020, 28(5): 563-570.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 by the authors.

This work is licensed under a Creative Commons Attribution 4.0 International License.
